| Literature DB >> 29618355 |
Susheel K Singh1,2,3, Régis Wendpayangde Tiendrebeogo1,2,3, Bishwanath Kumar Chourasia1,2,3, Ikhlaq Hussain Kana1,2,3, Subhash Singh4, Michael Theisen5,6,7.
Abstract
BACKGROUND: The production of recombinant proteins with proper conformation, appropriate post-translational modifications in an easily scalable and cost-effective system is challenging. Lactococcus lactis has recently been identified as an efficient Gram positive cell factory for the production of recombinant protein. We and others have used this expression host for the production of selected malaria vaccine candidates. The safety of this production system has been confirmed in multiple clinical trials. Here we have explored L. lactis cell factories for the production of 31 representative Plasmodium falciparum antigens with varying sizes (ranging from 9 to 90 kDa) and varying degree of predicted structural complexities including eleven antigens with multiple predicted structural disulfide bonds, those which are considered difficult-to-produce proteins.Entities:
Keywords: Disulfide-rich protein; Lactococcus lactis; Malaria; Merozoite antigens; Plasmodium falciparum
Mesh:
Substances:
Year: 2018 PMID: 29618355 PMCID: PMC5885415 DOI: 10.1186/s12934-018-0902-2
Source DB: PubMed Journal: Microb Cell Fact ISSN: 1475-2859 Impact factor: 5.328
Fig. 1Expression and Purification of target recombinant proteins in L. lactis. a Left panel: Schematic representation for cloning and expression of target recombinant proteins from P. falciparum antigens without (i) and with (ii) carrier fusion protein; Right panel: Classification of the target recombinant proteins based on their cysteine content (constructs containing two or more cysteine residues are classified as cysteine-rich proteins) and the overall success rates for production of target recombinant proteins by the respective L. lactis expression clones using strategy (i) or (ii). b Expression and purification of recombinant cMSP33D7 (a representative recombinant protein which does not contain cysteine residues and expressed successfully in L. lactis without carrier fusion protein); Left panel: Coomassie blue-stained non-reducing SDS-PAGE analysis showing purification of recombinant cMSP33D7protein secreted in L. lactis culture supernatant; Lane 1: raw culture supernatant, lane 2: Ni+-NTA purified cMSP33D7; lane 3: Ion-exchange purified cMSP33D7; Right panel: Western Blot analysis of recombinant cMSP33D7 using anti-His antibody. c Expression and purification of recombinant R0-MSPDBL2 (a representative cysteine-rich recombinant protein and which was expressed successfully in L. lactis with GLURP-R0 as a carrier fusion protein); Left panel: Coomassie blue-stained non-reducing SDS-PAGE analysis showing purification of recombinant R0-MSPDBL2 protein secreted in L. lactis culture supernatant; Middle panel: Western blot analysis of recombinant R0-MSPDBL2 using anti-His antibody; and Right panel: Western blot analysis of recombinant R0-MSPDBL2 using anti-GLURP-R0 antibody; Lane 1: raw culture supernatant; lane 2: Affinity purified R0-MSPDBL2 recombinant protein; lane 3: TEV cleavage of recombinant R0-MSPDBL2 and SDS-PAGE separation of R0 and MSPDBL2 fragments; Lane 4: Ion-exchange chromatography separates cleaved R0 carrier protein after TEV protease cleavage and Lane 5: Purified recombinant MSPDBL2 obtained after TEV cleavage and ion-exchange chromatography. The arrow-heads indicate positions of cMSP33D7 and MSPDBL2 recombinant proteins in respective panels. Numbers shown on the left hand side of the gel pictures represent positions of protein molecular weight markers in kDa
Characteristics and purification strategies of recombinant proteins
| Antigena | Accession number | Target sequence | Cysteine (no) | Disorder tendencyb | Expression level | Capturing | Polishing | Mass (Da) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No carrier | With carrier | IMAC | Heat | IEC | Yield (mg/l)c | Calculated | Observedd | |||||
| GPI-anchored | ||||||||||||
| MSP119k | PFI1475W | N1607–N1702 | 12 | 0 | High | X | A | 30 | 12.2 | 15 | ||
| MSP23D7 | PFB0300C | A111–G238 | 0 | 100 | High | X | A | 20 | 13.7 | 40 | ||
| MSP2FC27 | E143–G230 | 0 | 94 | High | X | A | 20 | 9.6 | 25 | |||
| Pf12 | PFF0615C | K155–S323 | 6 | 0 | Low | Med | X | C | 10 | 20 | 20 | |
| Pf38 | PFE0395C | K139–I327 | 6 | 0 | Low | Med | X | C | 10 | 23 | 25 | |
| Peripherally associated | ||||||||||||
| nMSP33D7 | PF10_0345 | N21–L182 | 1 | 25 | High | X | A | 40 | 17.6 | 27 | ||
| cMSP33D7 | PF10_0345 | K183–H354 | 0 | 0 | High | X | A | 18 | 20 | 30 | ||
| nMSP3K1 | PFU08851 | N21–L208 | 0 | 48 | High | X | A | 35 | 21 | 37 | ||
| MSP6 | PF10_346 | Y17–N160 | 0 | 70 | Med | X | A | 10 | 17.5 | 23 | ||
| MSP3.3 | PF10_0347 | Q23–T227 | 0 | 48 | Med | X | A | 7 | 22.3 | 37 | ||
| MSP3.7 | PF10_0352 | K27–R213 | 0 | 100 | Med | X | A | 7 | 20.9 | 37 | ||
| GLURP-R0 | AAA50613 | T27–A500 | 0 | 99 | High | X | A | 75 | 54.3 | 90 | ||
| GLURP-R2 | AAA50613 | V705–1177 | 0 | 78 | High | X | A | 35 | 53 | 110 | ||
| SERA5 | PF02_0072 | K17–192/226–S382 | 8 | 40 | Low | High | X | C | 17 | 35.5 | 38 | |
| Pf41 | PFD0240C | S231–S378 | 6 | 0 | Low | Med | X | C | 7 | 18 | 18 | |
| MSPDBL1 | PF10_0348 | K143–D443 | 13 | 0 | Low | Med | X | C | 8 | 37 | 37 | |
| MSPDBL2 | PF10_0355 | K161–L457 | 12 | 0 | Low | High | X | C | 15 | 36.5 | 35 | |
| MSPDBL1 (Leucine) | PF10_0348 | D508–K697 | 0 | 69 | Med | X | A | 7 | 22 | 35 | ||
| Micronemal/microneme | ||||||||||||
| EBA140RIII–V | MAL13P1.60 | E746–T1045 | 0 | 93 | High | X | A | 16 | 32.9 | 40 | ||
| EBA140 RII | MAL13P1.60 | Q146–K710 | 23 | 0 | Low | Low | X | C | 1,5 | 67.3 | 85 | |
| GAMA | PF08_0008 | N25–H337 | 7 | 10 | Low | Med | X | A | 5 | 36.8 | 45 | |
| RIPR | PFC1045C | K279–D995 | 75 | 0 | Low | Low | X | A | 1 | 82.3 | 110 | |
| SUB2 | PF11_0381 | K14–N681 | 2 | 29 | Low | Med | X | A | 5 | 78.3 | 90 | |
| Rhoptry | ||||||||||||
| PfRh2b | MAL13P1.176 | L2790–K3184 | 0 | 91 | Med | X | A | 8 | 44.7 | 120 | ||
| PfRh2a | PF13_0198 | H2874–S3060 | 0 | 26 | High | X | A | 13 | 22 | 25 | ||
| PfRh4.2 | PFD1150C | L1275–I1451 | 0 | 11 | Low | Med | X | C | 2 | 21.5 | 21 | |
| PfRh2-2030 | PF13_0198 | E2030–Q2528 | 1 | 0 | Med | X | A | 8 | 58 | 58 | ||
| RAMA | MAL7P1.208 | I42–N786 | 0 | 100 | Low | Med | X | A | 7 | 90.6 | 120 | |
| RALP-1 | MAL7P1.119 | N396–P634 | 0 | 47 | Low | Med | X | A | 10 | 27 | 37 | |
| RON2 | PF14_0495 | I775–K958 | 0 | 49 | Med | X | A | 10 | 24 | 25 | ||
| RON4 | PF11_0168 | K25–L709 | 0 | 100 | Low | Med | X | A | 9 | 76 | 150 | |
A anion exchange (HiTrap Q HP); C cation exchange (Hitrap SP HP)
aGene originate from 3D7 unless otherwise stated
bDisorder prediction score was calculated by using IUPred [41]
cThe levels of expressed protein was determined by BCA kit after final step purification. Expression levels are grouped into “low” (0.1–2 mg/l), “medium” (2–10 mg/l), and “high” (> 10 mg/l)
dBy SDS-PAGE
Fig. 2Purification of target recombinant protein by heat-treatment. a Heat treatment of L. lactis raw culture supernatant expressing recombinant MSPDBL2; Left panel: Coomassie blue stained SDS-PAGE analysis of MSPDBL2 containing supernatant before (lane 1) and after (lane 2) heat treatment; Right panel: Corresponding Western blot probed with anti-His antibodies. b Heat treatment of L. lactis raw culture supernatant expressing R0-MSPDBL2 fusion protein; Left panel: Coomassie blue stained SDS-PAGE analysis of R0-MSPDBL2 containing culture supernatant before (lane 1) and after (lane 2) heat treatment; lane 3: TEV protease treatment of recombinant R0-MSPDBL2 and ion-exchange chromatography based separation of R0 fusion partner (lane 4) and MSPDBL2 (lane 5) fragments after TEV protease cleavage of R0-MSPDBL2 derived from heat treated culture supernatant; Right panel: Corresponding Western blot probed with anti-His antibodies. The arrow-heads indicate the position of MSPDBL2 fragment. c Size exclusion chromatography analysis of purified recombinant MSPDBL2 as obtained from L. lactis culture supernatants expressing R0-MSPDBL2 (left panel) and MSPDBL2 expressed without carrier fusion partner (right panel). SE-HPLC was performed under native conditions in a phosphate buffer pH 7.2 to determine the amount of monomer in the sample. d Comparative antigenicity assessment of purified recombinant MSPDBL2 protein. The scatter-plot shows Pearson’s co-relation coefficient between the ELISA values observed for reactivity of a panel of 54 malaria hyperimmune Liberian sera samples against the recombinant MSPDBL2 protein preparations purified by heat treatment (y-axis) or without heat (x-axis)
Fig. 3Characterization of cysteine-rich recombinant proteins purified by heat treatment method. Left panel: Coomassie blue-stained SDS-PAGE analysis of purified recombinant proteins under non-reducing or under reducing (upon treatment with DTT) conditions. Lanes 1: pf12; 2: SERA5; 3: Pf41; 4: MSPDBL1; 5: MSPDBL2; 6: Pf38; 7: EBA140 RII; 8: GAMA; 9: RIPR and 10: SUB2. Right panel: Corresponding Western Blot analysis using anti-His antibody
Fig. 4Antigenic analysis of different target recombinant proteins expressed and purified from L. lactis culture. Total IgG prevalence as observed in 54 malaria hyperimmune Liberian sera against purified recombinant proteins as determined through multiplex analysis. a Antigenic analysis of recombinant proteins derived from membrane anchored P. falciparum antigens which include the GPI-anchored and transmembrane domain containing antigens from secretory organelles (micronemes and rhoptries). b Antigenic analysis of recombinant proteins derived from P. falciparum antigens which are peripherally associated with merozoite surface. The horizontal lines mark the cutoff-levels determined by the mean fluorescence intensity (MFI) +2 standard deviations of reactivity of sera from Danish donors who have never been exposed to malaria infection. The numbers listed above scatter plot for each antigen represent the percentage of hyperimmune sera which show positive reactivity against the respective antigen